Skip to main content

Site notifications

Post-market review of spinal cord stimulator devices

Published

Related content

  • TGA confirms decision to not register lecanemab (LEQEMBI)

    Following a request from the sponsor to reconsider their decision, the TGA has confirmed the initial decision to not register the medicine on the basis that the safety and efficacy of the medicine were not satisfactorily established.
  • TGA's decision to not register lecanemab (LEQEMBI)

    TGA has made the decision not to register lecanemab (LEQEMBI) for the treatment of patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and Mild Alzheimer's dementia (early Alzheimer's disease).